dymista 137+50 mikrog/dosis næsespray, suspension
2care4 aps - azelastinhydrochlorid, fluticasonpropionat - næsespray, suspension - 137+50 mikrog/dosis
lamictal 100 mg tyggetabletter/dispergible tabletter
glaxosmithkline pharma a/s - lamotrigin - tyggetabletter/dispergible tabletter - 100 mg
lamictal 200 mg tyggetabletter/dispergible tabletter
glaxosmithkline pharma a/s - lamotrigin - tyggetabletter/dispergible tabletter - 200 mg
lamictal 25 mg tyggetabletter/dispergible tabletter
glaxosmithkline pharma a/s - lamotrigin - tyggetabletter/dispergible tabletter - 25 mg
lamictal 50 mg tyggetabletter/dispergible tabletter
glaxosmithkline pharma a/s - lamotrigin - tyggetabletter/dispergible tabletter - 50 mg
lamictal 5 mg tyggetabletter/dispergible tabletter
glaxosmithkline pharma a/s - lamotrigin - tyggetabletter/dispergible tabletter - 5 mg
pombiliti
amicus therapeutics europe limited - cipaglucosidase alfa - glycogen opbevaring sygdom type ii - andre alimentary tract and metabolism produkter, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).
dymista 137+50 mikrog/dosis næsespray, suspension
viatris aps - azelastinhydrochlorid, fluticasonpropionat - næsespray, suspension - 137+50 mikrog/dosis
dymista 137+50 mikrog/dosis næsespray, suspension
orifarm a/s - azelastinhydrochlorid, fluticasonpropionat - næsespray, suspension - 137+50 mikrog/dosis
dymista 137+50 mikrog/dosis næsespray, suspension
paranova danmark a/s - azelastinhydrochlorid, fluticasonpropionat - næsespray, suspension - 137+50 mikrog/dosis